LOXO-338 + Pirtobrutinib
Phase 1Active 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Leukemia, Lymphocytic, Chronic, B-Cell
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone, Lymphoma, Non-Hodgkin, Multiple Myeloma, B-cell Lymphoma, Waldenstrom Macroglobulinemia, Lymphoma, Mantle-Cell
Trial Timeline
Sep 30, 2021 → Jun 1, 2026
NCT ID
NCT05024045About LOXO-338 + Pirtobrutinib
LOXO-338 + Pirtobrutinib is a phase 1 stage product being developed by Eli Lilly for Leukemia, Lymphocytic, Chronic, B-Cell. The current trial status is active. This product is registered under clinical trial identifier NCT05024045. Target conditions include Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-cell Marginal Zone, Lymphoma, Non-Hodgkin.
What happened to similar drugs?
20 of 20 similar drugs in Leukemia, Lymphocytic, Chronic, B-Cell were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
6
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05024045 | Phase 1 | Active |
Competing Products
20 competing products in Leukemia, Lymphocytic, Chronic, B-Cell